WO2022233398A1 - COMPOUNDS FOR REDUCING LIPOPROTEIN(a) - Google Patents
COMPOUNDS FOR REDUCING LIPOPROTEIN(a) Download PDFInfo
- Publication number
- WO2022233398A1 WO2022233398A1 PCT/EP2021/061679 EP2021061679W WO2022233398A1 WO 2022233398 A1 WO2022233398 A1 WO 2022233398A1 EP 2021061679 W EP2021061679 W EP 2021061679W WO 2022233398 A1 WO2022233398 A1 WO 2022233398A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tetrahydroxy
- acid
- compound
- cholan
- oic acid
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 39
- 108010033266 Lipoprotein(a) Proteins 0.000 title claims abstract description 9
- 102000057248 Lipoprotein(a) Human genes 0.000 title claims abstract 3
- 102100040214 Apolipoprotein(a) Human genes 0.000 claims abstract description 106
- 101710115418 Apolipoprotein(a) Proteins 0.000 claims abstract description 101
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Polymers C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims abstract description 37
- 230000036470 plasma concentration Effects 0.000 claims abstract description 34
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N 4-(3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoic acid Polymers OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 53
- 201000010099 disease Diseases 0.000 claims description 34
- 208000035475 disorder Diseases 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 11
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 9
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 208000006011 Stroke Diseases 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 7
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- 208000007536 Thrombosis Diseases 0.000 claims description 6
- 208000017169 kidney disease Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 230000023597 hemostasis Effects 0.000 claims description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 4
- 208000037411 Aortic calcification Diseases 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- 239000003529 anticholesteremic agent Substances 0.000 claims description 4
- 229940127226 anticholesterol agent Drugs 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 229960003080 taurine Drugs 0.000 claims description 4
- COCMFMBNEAMQMA-FOKRCTQASA-N 3alpha,6alpha,7beta,12alpha-Tetrahydroxy-5beta-cholan-24-oic Acid Chemical compound C([C@H]1[C@@H](O)[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 COCMFMBNEAMQMA-FOKRCTQASA-N 0.000 claims description 3
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims description 3
- 229940123239 Cholesterol synthesis inhibitor Drugs 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 2
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003613 bile acid Substances 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 26
- 230000014509 gene expression Effects 0.000 description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 17
- COCMFMBNEAMQMA-NQTCFNIESA-N 3alpha,6alpha,7alpha,12alpha-Tetrahydroxy-5beta-cholan-24-oic acid Chemical compound C([C@H]1[C@@H](O)[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 COCMFMBNEAMQMA-NQTCFNIESA-N 0.000 description 16
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 9
- 210000003494 hepatocyte Anatomy 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- -1 small molecule compound Chemical class 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 208000037998 chronic venous disease Diseases 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 230000009261 transgenic effect Effects 0.000 description 6
- 102100038495 Bile acid receptor Human genes 0.000 description 5
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 5
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 239000004380 Cholic acid Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 238000012404 In vitro experiment Methods 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 3
- 229960002471 cholic acid Drugs 0.000 description 3
- 235000019416 cholic acid Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101100055841 Danio rerio apoa1 gene Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 101150056612 PPIA gene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- QSHQKIURKJITMZ-BRPMRXRMSA-N cholane group Polymers [C@@H]1(CC[C@H]2[C@@H]3CCC4CCCC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCC QSHQKIURKJITMZ-BRPMRXRMSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 102000006255 nuclear receptors Human genes 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- OYYOMBJBKSVBJN-WSZRJFJKSA-N (4R)-4-[(8R,9S,10S,13R,14S,17R)-15,15,16,16-tetrahydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical compound OC1(C([C@@H]([C@]2(CC[C@@H]3[C@]4(CCCCC4CC[C@H]3[C@H]12)C)C)[C@H](C)CCC(O)=O)(O)O)O OYYOMBJBKSVBJN-WSZRJFJKSA-N 0.000 description 1
- WGGZRKVUOFMQHM-VCLVUCJPSA-N (4r)-4-[(8r,9s,10r,13r,14s,17r)-3,4,7,12-tetrahydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical compound OC1CC2C(O)C(O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)C(O)C2 WGGZRKVUOFMQHM-VCLVUCJPSA-N 0.000 description 1
- COCMFMBNEAMQMA-OPIZJWLHSA-N (4r)-4-[(8r,9s,10r,13r,14s,17r)-3,6,7,12-tetrahydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical compound OC1C(O)C2CC(O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)C(O)C2 COCMFMBNEAMQMA-OPIZJWLHSA-N 0.000 description 1
- UYVVLXVBEQAATF-KBXJPTNGSA-N 1,3,7,12-tetrahydroxycholan-24-oic acid Chemical compound OC1CC2CC(O)CC(O)[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)C(O)C2 UYVVLXVBEQAATF-KBXJPTNGSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- IMMADCCLTPCOKH-UHFFFAOYSA-N 4-(2,3,7,12-tetrahydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoic acid Chemical compound OC1CC2CC(O)C(O)CC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 IMMADCCLTPCOKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 206010050559 Aortic valve calcification Diseases 0.000 description 1
- 208000027896 Aortic valve disease Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108010072220 Cyclophilin A Proteins 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 229940127355 PCSK9 Inhibitors Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010045254 Type II hyperlipidaemia Diseases 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- HPYIIXJJVYSMCV-MGDXKYBTSA-N astressin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]1C(N[C@@H](C)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@@H](CCCCNC(=O)CC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)=O)C(C)C)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CNC=N1 HPYIIXJJVYSMCV-MGDXKYBTSA-N 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- RPKLZQLYODPWTM-KBMWBBLPSA-N cholanoic acid Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 RPKLZQLYODPWTM-KBMWBBLPSA-N 0.000 description 1
- 125000003716 cholic acid group Chemical group 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 238000010842 high-capacity cDNA reverse transcription kit Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 102000027483 retinoid hormone receptors Human genes 0.000 description 1
- 108091008679 retinoid hormone receptors Proteins 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 125000001612 ursodeoxycholic acid group Chemical group 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to the use of polyhydroxylated bile acid compounds in the treatment of a subject suffering from an increased plasma level of lipoprotein (a).
- Cholesterol is a ubiquitous biological substance produced in numerous human organs and cells. It has important physiological functions such as stabilization of cell membranes, precursor of bile acids and steroid hormones. On the other hand, any excess of cholesterol is deleterious and causes numerous diseases among them coronary heart disease, myocardial infarction and stroke. [0003] Cholesterol is transported in blood in several lipoproteins: Very-low-, low-, and high-density lipoproteins (VLDL, LDL, and HDL). Whereas HDL is considered to be beneficial, excess VLDL and LDL are detrimental. There are several medications available to treat subjects with elevated LDL- and VLDL-cholesterol efficiently.
- VLDL Very-low-, low-, and high-density lipoproteins
- Lp(a) lipoprotein(a)
- Lp(a) is considered to be even more atherogenic than LDL or VLDL.
- Lp(a) consists of an LDL-like core particle plus the characteristic antigen, Apo(a), a large glycoprotein with a molecular mass of about 500 kD.
- Apo(a) the characteristic antigen
- the liver is the central organ for the biosynthesis of all lipoproteins.
- Lp(a) is almost exclusively produced there.
- It is generally acknowledged that high plasma levels of Lp(a) are causally related to myocardial infarction and stroke. The plasma concentration of Lp(a) is highly skewed and great differences among various ethnic groups have been observed.
- the conventional cholesterol lowering medications such as statins, bile acid sequestrants, or fibrates have little if any effect on plasma Lp(a) concentrations and may even lead to increased Lp(a) levels.
- PCSK9 inhibitors relatively new drugs for lowering LDL-C may reduce Lp(a) up to 25%, but there are great inter-individual differences (Kostner, K.M., et a I., 2013. European Heart Journal, 34: 3268-3276). Nicotinic acid at higher doses may reduce Lp(a) levels up to 30% - yet this drug has been taken from the market in many countries because of unwanted side effects (Chennamsetty I. et a I., (2012) J. Lipid Res. 53: 2405-2412).
- Lp(a) is biosynthesized in the liver.
- Lp(a) plasma concentration is primarily determined by the rate of Apo(a) biosynthesis whereas the catabolic rate of Lp(a) has little impact.
- an effective medication should interfere with the synthesis rate of Apo(a).
- FXR Farnesoid-X Receptor
- Binding of ligands to FXR stimulates its transport to the nucleus and the interference with the binding of HNF4a, a positive transcription factor for Apo(a), to its response element and cessation of Apo(a) expression. Both mechanisms together lead to a blocking of Apo(a) transcription.
- Very effective FXR agonists are bile acids, in humans cholic acid, chenodeoxycholic acid deoxy cholic acid and different conjugated forms thereof. These bile acids - in particular the lipophilic ones - may be toxic at higher concentrations and not suitable for long-term medications. Furthermore, there are numerous bile acids and derivatives thereof that have no impact on plasma Lp(a) levels at all.
- ursodeoxycholic acid a compound used for the treatment of primary biliary cirrhosis.
- W02009105897A1 and WO2011022838A1 disclose polyhydroxylated bile acids for the treatment of biliary disorders.
- W02013041519A1 discloses compounds with a polyhydroxylated cholane skeleton for use as modulators of the retinoid-receptor related orphan receptor (ROR). Exemplified are different 1/3 ,3a,7a,12a-tetrahydroxy-5 3 -cholan-24-oate compounds. These compounds exhibited an improvement in insulin sensitivity in obese insulin resistant mice.
- ROR retinoid-receptor related orphan receptor
- the invention provides polyhydroxylated bile acids (PHBA) for the treatment of subjects with elevated Lp(a) levels.
- PHBA polyhydroxylated bile acids
- a polyhydroxylated bile acid compound or a pharmaceutically acceptable salt thereof for use in the treatment of a subject suffering from an increased plasma level of lipoprotein (a) (Lp(a)).
- the plasma level of Lp(a) in said subject is above the concentration by consensus recommendations of about >30 mg/dl.
- the plasma level of Lp(a) in said subject is decreased by at least 10% compared to the baseline value.
- the polyhydroxylated bile acid compound is conjugated to a pharmaceutically acceptable moiety.
- said pharmaceutically acceptable moiety is selected from the group consisting of amino sulfonic acid, an amine and amino acid.
- said pharmaceutically acceptable moiety is selected from the group consisting of ethanolamine, taurine, glycine or serine.
- the polyhydroxylated bile acid compound according to the invention is a tetrahydroxylated bile acid.
- the tetrahydroxylated bile acid according to the invention is selected from the group consisting of
- the tetrahydroxylated bile acid according to the invention is selected from the group consisting of
- the polyhydroxylated bile acid according to the invention is 3a, 6a, 7a, 12a-tetra hydroxy-5 b -cholan-24-oic acid.
- the increased plasma level of Lp(a) of the subject is the cause of an associated disease.
- the associated disease is one of hyperlipidemia, dyslipidemia, atherosclerosis, hypertension, thrombosis, disorder of hemostasis, cardiovascular disease, aortic calcification, stroke, kidney disease or Type-ll diabetes.
- the polyhydroxylated bile acid according to the invention is used in combination with a cholesterol lowering agent.
- said cholesterol lowering agent is a cholesterol synthesis inhibitor or a cholesterol absorption inhibitor.
- a pharmaceutical composition for use in the prevention or treatment of a disease associated with an increased Lp(a) plasma level in a subject comprising a polyhydroxylated bile acid compound according to the present invention and a pharmaceutical acceptable carrier.
- said disease is one of hyperlipidemia, dyslipidemia, atherosclerosis, hypertension, thrombosis, disorder of hemostasis, cardiovascular disease, aortic calcification, stroke, kidney disease or Type-ll diabetes.
- said disease is hyperlipidemia, dyslipidemia, hypertension, or Type-ll diabetes.
- Fig.l Primary hepatocytes from tg-Apo(a) mice were incubated for 24h with 3a,6a,7a,12a-tetrahydroxy-5 b -cholan-24-oic acid and the expression of Apo(a) was measured by RT-PCR. Values on the y-axis are relative expressions in relation to the control hepatocytes without THBA. Results are mean ⁇ SEM of three independent experiments. (**P ⁇ 0.01***P ⁇ 0.001).
- Fig. 2 Primary hepatocytes from tg-Apo(a) mice were incubated for 24h with 3a,6a,7a,12a-tetrahydroxy-5 b -cholan-24-oic acid and the expression of Cyp7al was measured by RT-PCR. Values on the y-axis are relative expressions in relation to the control hepatocytes without TPIBA. Results are mean ⁇ SEM of three independent experiments. (***P ⁇ 0.001).
- Fig. 3 8 tg-Apo(a) mice were fed for 1 week with 0.1% 3a, 6a, 7a, 12a- tetrahydroxy-5 b -cholan-24-oic acid and the expression of Apo(a) and Cyp7al was measured by RT-PCR. Values on the y-axis are relative expressions in relation to the control animals fed with chow diet without TPIBA. The data are mean ⁇ SEM from duplicate analyses. (***P ⁇ 0.001).
- Fig. 4 6 tg-Apo(a) mice were fed with 0.2% 3a,6a,7a,12a-tetrahydroxy- 5 b -cholan-24-oic acid for 1 week and the plasma concentration of Apo(a) was measured in duplicates by an ELISA from Mercodia ® . Values are in mg/dl of Apo(a).
- Fig. 5 6 tg-Apo(a) mice were fed with 1% 3a,6a,7a,12a-tetrahydroxy-5 b - cholan-24-oic acid for 2 weeks and the plasma concentration of Apo(a) was measured in duplicates by an ELISA from Mercodia ® . Values are in mg/dl of Apo(a).
- Bile acids are amphiphilic molecules with 24 carbon atoms and consist of a hydrophobic and a rigid steroid nucleus, to which hydrophilic hydroxyl groups and a flexible acidic aliphatic side chain are attached.
- the steroidal core of BAs constitutes a saturated cyclopentanoperhydrophenanthrene skeleton consisting of three six-membered rings (A, B, and C) and one five-membered ring (D).
- Cholanoic acid is the archetypal C24 bile acid skeleton from which all other C24 bile acids can be derived.
- 5 a and 5 b the latter isomer is the most biologically relevant.
- Most naturally occurring bile acids are characterized by hydroxyl groups in the A, B, and C ring of the cholane skeleton.
- the bile acid nucleus is curved because the A and the B rings are in a cvs-fused configuration.
- the BAs in lower vertebrates are known as allo-BAs. In this case, A and B rings are trans linked (5 a -stereochemistry).
- C 24 BAs constitute a major part of the bile.
- the BAs are facially amphipathic, i.e., they contain both hydrophobic (lipid soluble) and hydrophilic (polar) faces.
- polyhydroxylated bile acids refers to at least 4 hydroxy substituents and up to the maximal hydroxylation level of the bile acid compound.
- Polyhydroxylated bile acids include but are not limited to tetrahydroxylated, pentahydroxylated, hexahydroxylated bile acids, etc. According to one embodiment of the invention tetrahydroxylated bile acids are preferred.
- the polyhydroxylated bile acid compound according to the present invention is selected from the group consisting of tetrahydroxylated bile acids (THBA).
- the polyhydroxylated bile acid according to the present invention is selected from the group consisting of 3,6,7,12-tetrahydroxy- cholan-24-oic acid, 3,4,7,12-tetrahydroxy-cholan-24-oic acid, 1,3,7,12- tetrahydroxy-cholan-24-oic acid, 2,3,7,12-tetrahydroxy-cholan-24-oic acid, 2,4,7,12-cholan-24-oic acid, and 2,6,7,12-cholan-24-oic acid.
- the polyhydroxylated bile acid according to the present invention is selected from the group consisting of 3a, 6a, 7a, 12a- tetrahydroxy-5/3 -cholan-24-oic acid, 3a, 6/3 ,7a,12a-tetrahydroxy-5 b -cholan-24- oic acid, 3a, 6a, 7 b ,12a-tetrahydroxy-5 b -cholan-24-oic acid, 3a, 6a, 7a, 12 b - tetrahydroxy-5 3 -cholan-24-oic acid, 3a, 6/3 ,7a, 12/3 -tetrahydroxy-5 b -cholan-24- oic acid, and 3a, 6/3 ,7 b ,12/3 -tetrahydroxy-5/3 -cholan-24-oic acid, 1/3 ,3a, 7a, 12a tetrahydroxy-cholan-24-oic acid.
- the polyhydroxylated bile acid according to the present invention is 3a,6a,7a,12a-tetrahydroxy-5 b -cholan-24-oic acid.
- pharmaceutically acceptable salt refers to a formulation of a bile acid compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the bile acid.
- Pharmaceutical salts can also be obtained by reacting the compounds of this invention with a base to form a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt or a lithium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a zinc salt, a salt of organic bases such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl) methylamine, and salts thereof.
- the pharmaceutically acceptable salt is Na + , K + , Li + , Ca ++ , Mg ++ or Zn ++ .
- conjugated to refers to compounds, wherein the polyhydroxylated bile acid compound according to the present invention is conjugated to a pharmaceutically acceptable moiety.
- pharmaceutically acceptable moiety refers to a moiety which provides additional hydrophilicity, charge, function and/or other properties.
- the pharmaceutically acceptable moiety may after administration optionally be released in clinically acceptable amounts.
- the polyhydroxylated bile acid according to the present invention is conjugated to a suitable moiety.
- the polyhydroxylated bile acid is conjugated to an amino acid, e.g., taurine, glycine or serine.
- the bile acid according to the present invention is conjugated to an acid or a salt thereof, e.g., sulfate, phosphate, etc.; to a sulfonic acid or a salt thereof, e.g., alkyl sulfonate, etc.; organic acid or a thereof, e.g., acetate, lactate, malate, tartrate, citrate, ascorbate, succinate, butyrate, valerate, fumarate, glucuronate, etc.; to a sugar e.g., glucose, or xylose; to an amino sugar e.g., N- acetylglucosamine, glucosamine, or ethanolamine.
- the pharmaceutically acceptable moiety is taurine, glycine or serine.
- compositions can also be obtained by reacting a bile acid compound of the invention with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, succinic acid, tartaric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
- inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, succinic acid, tartaric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
- LDL-C Low density lipoprotein cholesterol
- CVD cardiovascular disease
- Lp(a) is both a highly prevalent risk factor and the most common monogenetic CVD risk factor.
- the average levels of Lp(a) differ among different groups and 20-30% population has plasma levels above the risk threshold of about 30 mg/dL (75 nmol/L) for CVD. In Blacks, the average levels of Lp(a) are significantly higher, and in Asians significantly lower. In these groups the cut-off levels where pharmacological treatment is recommended are distinct from Whites. The risk rises nearly linearly with increased Lp(a) levels. Since cholesterol lowering medications in most cases do not reduce Lp(a) levels to a desirable degree it is plausible to combine them with compounds of this invention.
- the polyhydroxylated bile acid is therefore administered in combination with a cholesterol synthesis inhibitor such as a statin or a cholesterol absorption inhibitor, e.g., Ezetimibe ® .
- plasma level of lipoprotein (a) refers to the concentration of Lp(a) in plasma given in mg/dL or nmol/L.
- a subject with an increased plasma level of Lp(a) compared to a desirable reference value plasma level of Lp(a) is treated with a polyhydroxylated bile acid.
- the desirable reference value of plasma lipoprotein(a) is considered as the value of plasma Lp(a) associated with a no or low cardiovascular risk. Said desirable value may vary regionally worldwide.
- a concentration of below 15 mg/dl or even of below 10 mg/dl is generally considered as a plasma level of Lp(a) associated with no or low cardiovascular risk.
- a plasma level of Lp(a) of above 30 mg/dl is considered as increased level associated with an increased risk.
- a plasma level of Lp(a) of above 60 mg/dl is considered as a condition where a therapeutic intervention is generally recommended by health professionals especially if co-occurring with additional risk factors such as high plasma LDL or low plasma HDL levels.
- the plasma level of Lp(a) of said subject is decreased by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, or at least 60% as compared to the baseline plasma level of Lp(a).
- the term “baseline” as used herein refers to the subject's lipoprotein (a) level determined prior to or at start of treatment. This baseline is the refence value for determining the effective decrease of the Lp(a) concentration in the subject’s plasma.
- the Lp(a) level may be determined by enzyme immunoassays (EIAs), by an immunoradiometric assay (IRMA), turbidimetry, nephelometry, liquid chromatography- mass spectroscopy, or by electrophoresis measuring Lp(a)- cholesterol.
- the present invention provides a pharmaceutical composition for use in the prevention or treatment of a disease associated with an increased plasma level of Lp(a), wherein said pharmaceutical composition comprises a polyhydroxylated bile acid compound and a pharmaceutical acceptable carrier.
- pharmaceutically acceptable carrier refers to a pharmaceutical carrier according to acceptable pharmaceutical techniques.
- the carrier may take a wide variety of forms depending on the form of preparation desired for administration.
- Various organic or inorganic carrier materials conventionally used as materials for pharmaceutical preparations may be used as pharmaceutically acceptable carrier for the compounds of the invention and the route of administration chosen. They are blended as excipient, lubricant, binder or disintegrant for solid preparations; and solvent, solubilizing agent, suspending agent, isotonicity agent, buffer, soothing agent and the like for liquid preparations.
- an additive for pharmaceutical preparations such as preservative, antioxidant, colorant, sweetening agent and the like can be used.
- treatment in relation to a given disease or disorder, includes, but is not limited to, inhibiting the disease or disorder, for example, arresting the development of the disease or disorder; relieving the disease or disorder, for example, causing regression of the disease or disorder; or relieving a condition caused by or resulting from the disease or disorder, for example, relieving, preventing or treating symptoms of the disease or disorder.
- prevention in relation to a given disease or disorder means: preventing the onset of disease development if none had occurred, preventing the disease or disorder from occurring in a subject that may be predisposed to the disorder or disease but has not yet been diagnosed as having the disorder or disease, and/or preventing further disease/disorder development if already present.
- the present invention relates to the treatment and prevention of a disease associated with an increased plasma level of Lp(a), wherein said associated disease refers to a disease, disorder of condition of a subject having family and/or personal histories of heart disease, lipid metabolism disorder, hypercholesterolemia, hypertriglyceridemia, dyslipidemia, high triglycerides and/or high blood cholesterol levels, non-fatal heart attack, non-fatal stroke, postmenopausal subjects with increased risk factors for heart disease, hypothyroidism, underactive thyroid gland, diabetes, renal disease, renal failure, nephrotic syndrome, hypertension, hemostasis disorders, thrombosis, aortic valve calcification.
- said associated disease refers to a disease, disorder of condition of a subject having family and/or personal histories of heart disease, lipid metabolism disorder, hypercholesterolemia, hypertriglyceridemia, dyslipidemia, high triglycerides and/or high blood cholesterol levels, non-fatal heart attack, non-fatal stroke, post
- the disease associated with an increased plasma level of Lp(a) is selected from the group consisting of atherosclerosis; stroke; vascular disease, e.g., cardiovascular disease, peripheral vascular disease, hereditary vascular disease; thrombosis; diabetes; metabolic disease conditions, e.g., dyslipoproteinemia, hyperlipidemia, etc.
- the disease associated with an increased plasma level of Lp(a) is type II diabetes, hyperlipidemia, or dyslipidemia.
- Example 1 -3a,6a,7a,12a-tetrahydroxy-5/3-cholan-24-oic acid reduces Apo(a) expression in transgenic Apo(a) mice - in vitro
- mice generated according to Frazer KA. et al. 1995 (Frazer KA, et al. (1995) Nat Genet. 1995;9(4):424-431) were used.
- Example 2 - 3a,6a,7a,12a-tetrahydroxy-53 ⁇ 4-cholanoic acid reduces Apo(a) expression in transgenic Apo(a) mice - in vivo
- mice generated previously (Frazer KA et al. (1995) Nat Genet. 1995;9(4):424-431) were used.
- THBA 3a,6a,7a,12a-tetrahydroxy-5 b -cholan-24- oic acid (MF: C24H40O6 MW: 424.57) > 95% purity was purchased from UHN Shanghai 88 Cailun Rd, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, 201210, China. All other chemicals were from Sigma-Aldrich https://www.sigmaaldrich.com if not stated otherwise.
- RNA expression was measured in primary hepatocytes as well as in whole liver extracts as described previously (Chennamsetty, I., et al. (2011) J. Clin. Invest. 121: 3724 - 3734; Chennamsetty, I., et al. (2012) Arterioscler. Thromb. Vase. Biol. 32: 1220 - 1227; Chennamsetty, I., et al. (2012) J. Lipid Res. 53: 2405-2412).
- total RNA was extracted using Trizol (Invitrogen) according to the manufacturer’s protocol. Two micrograms of total RNA were reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems).
- Quantitative real-time PCR was performed on a Light Cycler 480 instrument (Roche Diagnostics), using the QuantiFast SYBR Green PCR Kit (Qiagen).
- the following primer were used: Apo(a) mouse: Forward primer (5’ 3’) GGCACGTATGGCAGCAAGAT (SEQ ID NO:l); Reverse primer (5’ 3’) CCAAGGAGGAGGATTCAAACTG (SEQ ID NO:2); Ppia mouse: Forward primer (5’ 3’) TTCCAGGATTCATGTGCCAG (SEQ ID NO:3); Reverse primer (5’ 3’) CCATCCAGCCATTCAGTCTT (SEQ ID NO:4).
- Cyp7Al mouse Forward primer (5’ 3’) GGGATTGCTGTGGTAGTGAGC (SEQ ID NO:5); Reverse primer (5’ 3’) GGTATGGAATCAACCCGTTGTC (SEQ ID NO:6).
- Example 3 - 3a,6a,7a,12a-tetrahydroxy-5/3-cholan-24-oic acid reduces Apo(a) plasma concentrations in transgenic Apo(a) mice - in vivo Results of in vivo experiments:
- a known FXR agonist is cholic acid (3 a ,7 a ,12 a -trihydroxy-5 b -cholan- 24-oic acid), that in fact reduced plasma Apo(a) concentrations when fed to tg- Apo(a) mice. Due to its unwanted side effects cholic acid is not recommended for use as a medication because it may cause liver damage.
Abstract
The present invention relates to a polyhydroxylated bile acid compound or a pharmaceutically acceptable salt thereof for use in the treatment of a subject suffering from an increased plasma level of lipoprotein (a) (Lp(a)).
Description
COMPOUNDS FOR REDUCING LIPOPROTEIN(a)
Description
Field of the Invention
[0001] The present invention relates to the use of polyhydroxylated bile acid compounds in the treatment of a subject suffering from an increased plasma level of lipoprotein (a).
Background Art
[0002] Cholesterol is a ubiquitous biological substance produced in numerous human organs and cells. It has important physiological functions such as stabilization of cell membranes, precursor of bile acids and steroid hormones. On the other hand, any excess of cholesterol is deleterious and causes numerous diseases among them coronary heart disease, myocardial infarction and stroke. [0003] Cholesterol is transported in blood in several lipoproteins: Very-low-, low-, and high-density lipoproteins (VLDL, LDL, and HDL). Whereas HDL is considered to be beneficial, excess VLDL and LDL are detrimental. There are several medications available to treat subjects with elevated LDL- and VLDL-cholesterol efficiently.
[0004] A subfraction of the cholesterol-rich lipoproteins is lipoprotein(a) (Lp(a)). Lp(a) is considered to be even more atherogenic than LDL or VLDL. Lp(a) consists of an LDL-like core particle plus the characteristic antigen, Apo(a), a large glycoprotein with a molecular mass of about 500 kD. The liver is the central organ for the biosynthesis of all lipoproteins. Lp(a) is almost exclusively produced there. [0005] It is generally acknowledged that high plasma levels of Lp(a) are causally related to myocardial infarction and stroke. The plasma concentration of Lp(a) is highly skewed and great differences among various ethnic groups have been observed. In the Western populations where high plasma levels of cholesterol and atherosclerotic diseases prevail, individuals with Lp(a) levels higher than 30 - 50 mg/dl are at an increased risk. The risk strongly rises with increased Lp(a) plasma concentrations. Plasma Lp(a) concentrations are rather stable and hardly influenced by diet. Under certain disease conditions on the other hand, there may be great fluctuations in Lp(a) abundance: Subjects with liver diseases may have reduced and those with kidney diseases may have largely increased plasma levels. [0006] There are currently no registered drugs specific for lowering Lp(a) concentrations to a significant degree. The conventional cholesterol lowering
medications such as statins, bile acid sequestrants, or fibrates have little if any effect on plasma Lp(a) concentrations and may even lead to increased Lp(a) levels. [0007] PCSK9 inhibitors, relatively new drugs for lowering LDL-C may reduce Lp(a) up to 25%, but there are great inter-individual differences (Kostner, K.M., et a I., 2013. European Heart Journal, 34: 3268-3276). Nicotinic acid at higher doses may reduce Lp(a) levels up to 30% - yet this drug has been taken from the market in many countries because of unwanted side effects (Chennamsetty I. et a I., (2012) J. Lipid Res. 53: 2405-2412). There are also anecdotical reports on the effect of some functional foods that may reduce Lp(a) by 10 - 20 %, yet studies on a large collective are still missing. The most promising medication that is currently in phase-ill trials are anti-sense oligonucleotides.
[0008] Lp(a) is biosynthesized in the liver. Lp(a) plasma concentration is primarily determined by the rate of Apo(a) biosynthesis whereas the catabolic rate of Lp(a) has little impact. Thus, it is envisaged that an effective medication should interfere with the synthesis rate of Apo(a).
[0009] Farnesoid-X Receptor (FXR) is a key regulator of bile acid biosynthesis in humans. A similar regulatory mechanism was identified for Apo(a) transcription (Chennamsetty I., et al. (2011) J. Clin. Invest. 121: 3724 - 3734). FXR is a nuclear receptor that interferes with the promoter activity of target genes. In gut, FXR promotes the synthesis of FGF19 that binds to a specific receptor on liver cells and activates a signaling cascade that finally stops Apo(a) transcription. Binding of ligands to FXR on the other hand stimulates its transport to the nucleus and the interference with the binding of HNF4a, a positive transcription factor for Apo(a), to its response element and cessation of Apo(a) expression. Both mechanisms together lead to a blocking of Apo(a) transcription.
[0010] Very effective FXR agonists are bile acids, in humans cholic acid, chenodeoxycholic acid deoxy cholic acid and different conjugated forms thereof. These bile acids - in particular the lipophilic ones - may be toxic at higher concentrations and not suitable for long-term medications. Furthermore, there are numerous bile acids and derivatives thereof that have no impact on plasma Lp(a) levels at all. One example is ursodeoxycholic acid, a compound used for the treatment of primary biliary cirrhosis.
[0011] W02009105897A1 and WO2011022838A1 disclose polyhydroxylated bile acids for the treatment of biliary disorders. W02013041519A1 discloses
compounds with a polyhydroxylated cholane skeleton for use as modulators of the retinoid-receptor related orphan receptor (ROR). Exemplified are different 1/3 ,3a,7a,12a-tetrahydroxy-5 3 -cholan-24-oate compounds. These compounds exhibited an improvement in insulin sensitivity in obese insulin resistant mice. [0012] In summary, the effect of the state-of-the-art compounds on plasma Lp(a) levels has not been demonstrated so far. Thus, there is still an urgent need for small molecule compound medication for an efficient treatment of elevated Lp(a) levels in a subject.
Summary of invention
[0013] It is the object of the present invention to provide a small molecule compound medication for an efficient treatment of elevated Lp(a) levels in a subject in need thereof.
[0014] The objective is solved by the present invention.
[0015] The invention provides polyhydroxylated bile acids (PHBA) for the treatment of subjects with elevated Lp(a) levels. Thereby, the usefulness of polyhydroxylated bile acids (PHBA) for the treatment of subjects with elevated Lp(a) was evaluated. Transgenic mice were fed with PHBA to demonstrate a profound reduction of plasma Lp(a) concentrations.
[0016] According to the invention there is provided a polyhydroxylated bile acid compound or a pharmaceutically acceptable salt thereof for use in the treatment of a subject suffering from an increased plasma level of lipoprotein (a) (Lp(a)).
[0017] According to one aspect, the plasma level of Lp(a) in said subject is above the concentration by consensus recommendations of about >30 mg/dl.
[0018] According to another aspect, the plasma level of Lp(a) in said subject is decreased by at least 10% compared to the baseline value.
[0019] According to another aspect, the polyhydroxylated bile acid compound is conjugated to a pharmaceutically acceptable moiety.
[0020] Specifically, said pharmaceutically acceptable moiety is selected from the group consisting of amino sulfonic acid, an amine and amino acid.
[0021] Specifically, said pharmaceutically acceptable moiety is selected from the group consisting of ethanolamine, taurine, glycine or serine.
[0022] Specifically, the polyhydroxylated bile acid compound according to the invention is a tetrahydroxylated bile acid.
[0023] Specifically, the tetrahydroxylated bile acid according to the invention is selected from the group consisting of
3.6.7.12-tetrahydroxy-cho la n-24-oic acid,
3.4.7.12-tetrahydroxy-cho la n-24-oic acid,
1.3.7.12-tetrahydroxy-cho la n-24-oic acid,
2.3.7.12-tetrahydroxy-cho la n-24-oic acid,
2.4.7.12-tetrahydroxy-cholan-24-oic acid, and
2.6.7.12-tetrahydroxy-cho la n-24-oic acid.
[0024] Specifically, the tetrahydroxylated bile acid according to the invention is selected from the group consisting of
3a,6a,7a,12a-tetrahydroxy-5 3 -cholan-24-oic acid,
3a, 6/3 ,7a,12a-tetrahydroxy-5 b -cholan-24-oic acid,
3a, 6a, 7 b ,12a-tetra hydroxy-5 b -cholan-24-oic acid,
3a, 6a, 7a, 12/3 -tetrahydroxy-5 b -cholan-24-oic acid,
3a, 6/3 ,7a, 12/3 -tetrahydroxy-5 b -cholan-24-oic acid,
3a, 6/3 ,7 b ,12/3 -tetrahydroxy-5 b -cholan-24-oic acid, and 1 b ,3a, 7a, 12a- tetrahydroxy-cholan-24-oic acid.
[0025] Specifically, the polyhydroxylated bile acid according to the invention is 3a, 6a, 7a, 12a-tetra hydroxy-5 b -cholan-24-oic acid.
[0026] According to one aspect of the compound for use of the present invention, the increased plasma level of Lp(a) of the subject is the cause of an associated disease.
[0027] Specifically, the associated disease is one of hyperlipidemia, dyslipidemia, atherosclerosis, hypertension, thrombosis, disorder of hemostasis, cardiovascular disease, aortic calcification, stroke, kidney disease or Type-ll diabetes.
[0028] According to another aspect, the polyhydroxylated bile acid according to the invention is used in combination with a cholesterol lowering agent.
[0029] Specifically, said cholesterol lowering agent is a cholesterol synthesis inhibitor or a cholesterol absorption inhibitor.
[0030] According to one embodiment of the invention, there is provided a pharmaceutical composition for use in the prevention or treatment of a disease associated with an increased Lp(a) plasma level in a subject comprising a polyhydroxylated bile acid compound according to the present invention and a pharmaceutical acceptable carrier.
[0031] Specifically, said disease is one of hyperlipidemia, dyslipidemia, atherosclerosis, hypertension, thrombosis, disorder of hemostasis, cardiovascular disease, aortic calcification, stroke, kidney disease or Type-ll diabetes.
[0032] Specifically, said disease is hyperlipidemia, dyslipidemia, hypertension, or Type-ll diabetes.
Brief description of drawings
[0033] Fig.l: Primary hepatocytes from tg-Apo(a) mice were incubated for 24h with 3a,6a,7a,12a-tetrahydroxy-5 b -cholan-24-oic acid and the expression of Apo(a) was measured by RT-PCR. Values on the y-axis are relative expressions in relation to the control hepatocytes without THBA. Results are mean ± SEM of three independent experiments. (**P<0.01***P<0.001).
[0034] Fig. 2: Primary hepatocytes from tg-Apo(a) mice were incubated for 24h with 3a,6a,7a,12a-tetrahydroxy-5 b -cholan-24-oic acid and the expression of Cyp7al was measured by RT-PCR. Values on the y-axis are relative expressions in relation to the control hepatocytes without TPIBA. Results are mean ± SEM of three independent experiments. (***P<0.001).
[0035] Fig. 3: 8 tg-Apo(a) mice were fed for 1 week with 0.1% 3a, 6a, 7a, 12a- tetrahydroxy-5 b -cholan-24-oic acid and the expression of Apo(a) and Cyp7al was measured by RT-PCR. Values on the y-axis are relative expressions in relation to the control animals fed with chow diet without TPIBA. The data are mean ± SEM from duplicate analyses. (***P<0.001).
[0036] Fig. 4: 6 tg-Apo(a) mice were fed with 0.2% 3a,6a,7a,12a-tetrahydroxy- 5 b -cholan-24-oic acid for 1 week and the plasma concentration of Apo(a) was measured in duplicates by an ELISA from Mercodia®. Values are in mg/dl of Apo(a).
[0037] Fig. 5: 6 tg-Apo(a) mice were fed with 1% 3a,6a,7a,12a-tetrahydroxy-5 b - cholan-24-oic acid for 2 weeks and the plasma concentration of Apo(a) was measured in duplicates by an ELISA from Mercodia®. Values are in mg/dl of Apo(a).
Description of embodiments
[0038] Unless indicated or defined otherwise, all terms used herein have their usual meaning in the art, which will be clear to the skilled person.
[0039] Bile acids (BAs) are amphiphilic molecules with 24 carbon atoms and consist of a hydrophobic and a rigid steroid nucleus, to which hydrophilic hydroxyl
groups and a flexible acidic aliphatic side chain are attached. The steroidal core of BAs constitutes a saturated cyclopentanoperhydrophenanthrene skeleton consisting of three six-membered rings (A, B, and C) and one five-membered ring (D).
(cyclopentanoperhydrophenanthrene ring)
[0040] Cholanoic acid is the archetypal C24 bile acid skeleton from which all other C24 bile acids can be derived. Of the two common isomers: 5 a and 5 b , the latter isomer is the most biologically relevant.
(5 a -cholan-24-oic acid) (5 b -cholan-24-oic acid)
[0041] Most naturally occurring bile acids are characterized by hydroxyl groups in the A, B, and C ring of the cholane skeleton. In higher vertebrates, the bile acid nucleus is curved because the A and the B rings are in a cvs-fused configuration. In addition, there are angular methyl groups at positions C-10 and C-13. The BAs in lower vertebrates are known as allo-BAs. In this case, A and B rings are trans linked (5 a -stereochemistry). In higher vertebrates, C24 BAs constitute a major part of the bile. The BAs are facially amphipathic, i.e., they contain both hydrophobic (lipid soluble) and hydrophilic (polar) faces.
[0042] Specifically, in unconjugated polyhydroxylated bile acids the hydrophilic character of the compounds prevails. Polyhydroxylated as used herein refers to at least 4 hydroxy substituents and up to the maximal hydroxylation level of the bile acid compound. Polyhydroxylated bile acids include but are not limited to tetrahydroxylated, pentahydroxylated, hexahydroxylated bile acids, etc. According to one embodiment of the invention tetrahydroxylated bile acids are preferred. [0043] In one embodiment, the polyhydroxylated bile acid compound according to the present invention is selected from the group consisting of tetrahydroxylated bile acids (THBA).
[0044] In another embodiment, the polyhydroxylated bile acid according to the present invention is selected from the group consisting of 3,6,7,12-tetrahydroxy- cholan-24-oic acid, 3,4,7,12-tetrahydroxy-cholan-24-oic acid, 1,3,7,12- tetrahydroxy-cholan-24-oic acid, 2,3,7,12-tetrahydroxy-cholan-24-oic acid, 2,4,7,12-cholan-24-oic acid, and 2,6,7,12-cholan-24-oic acid.
[0045] In a specific embodiment, the polyhydroxylated bile acid according to the present invention is selected from the group consisting of 3a, 6a, 7a, 12a- tetrahydroxy-5/3 -cholan-24-oic acid, 3a, 6/3 ,7a,12a-tetrahydroxy-5 b -cholan-24- oic acid, 3a, 6a, 7 b ,12a-tetrahydroxy-5 b -cholan-24-oic acid, 3a, 6a, 7a, 12 b - tetrahydroxy-5 3 -cholan-24-oic acid, 3a, 6/3 ,7a, 12/3 -tetrahydroxy-5 b -cholan-24- oic acid, and 3a, 6/3 ,7 b ,12/3 -tetrahydroxy-5/3 -cholan-24-oic acid, 1/3 ,3a, 7a, 12a tetrahydroxy-cholan-24-oic acid.
[0046] In a specific aspect, the polyhydroxylated bile acid according to the present invention is 3a,6a,7a,12a-tetrahydroxy-5 b -cholan-24-oic acid.
[0047] The polyhydroxylated bile acids may be substituted by suitable substituent which do not alter the pharmaceutical activity of the compounds. Suitable substituents are for example selected from the group consisting of =0, -C1-3alkyl, - OC-L 3a I ky I , or halogen.
[0048] The term "pharmaceutically acceptable salt" refers to a formulation of a bile acid compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the bile acid. Pharmaceutical salts can also be obtained by reacting the compounds of this invention with a base to form a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt or a lithium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a zinc salt, a salt of organic bases such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl) methylamine, and salts thereof. In some embodiments, the pharmaceutically acceptable salt is Na+, K+, Li+, Ca++, Mg++ or Zn++.
[0049] The term “conjugated to" refers to compounds, wherein the polyhydroxylated bile acid compound according to the present invention is conjugated to a pharmaceutically acceptable moiety.
[0050] As used herein the term “pharmaceutically acceptable moiety" refers to a moiety which provides additional hydrophilicity, charge, function and/or other properties. The pharmaceutically acceptable moiety may after administration optionally be released in clinically acceptable amounts.
[0051] In one aspect, the polyhydroxylated bile acid according to the present invention is conjugated to a suitable moiety. In one aspect, the polyhydroxylated bile acid is conjugated to an amino acid, e.g., taurine, glycine or serine. In yet another aspect, the bile acid according to the present invention is conjugated to an acid or a salt thereof, e.g., sulfate, phosphate, etc.; to a sulfonic acid or a salt thereof, e.g., alkyl sulfonate, etc.; organic acid or a thereof, e.g., acetate, lactate, malate, tartrate, citrate, ascorbate, succinate, butyrate, valerate, fumarate, glucuronate, etc.; to a sugar e.g., glucose, or xylose; to an amino sugar e.g., N- acetylglucosamine, glucosamine, or ethanolamine. In some embodiments, the pharmaceutically acceptable moiety is taurine, glycine or serine.
[0052] Pharmaceutical modifications can also be obtained by reacting a bile acid compound of the invention with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, succinic acid, tartaric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
[0053] Lowering elevated low density lipoprotein cholesterol (LDL-C) is considered to be responsible for reducing cardiovascular disease (CVD; inclusive of
myocardial infarction, stroke and peripheral arterial disease). Thus, all clinicians taking care of subjects at risk of or with preexisting CVD needed to incorporate lipid management in their practice, particularly in managing elevated LDL-C.
[0054] Although the main focus of CVD prevention in the lipid arena has been on lowering LDL-C, elevated Lp(a) has emerged in the last decade as a genetic, independent and likely causal risk factor for CVD and calcific aortic valve disease (CAVD) as well as many other diseases.
[0055] Lp(a) is both a highly prevalent risk factor and the most common monogenetic CVD risk factor. The average levels of Lp(a) differ among different groups and 20-30% population has plasma levels above the risk threshold of about 30 mg/dL (75 nmol/L) for CVD. In Blacks, the average levels of Lp(a) are significantly higher, and in Asians significantly lower. In these groups the cut-off levels where pharmacological treatment is recommended are distinct from Whites. The risk rises nearly linearly with increased Lp(a) levels. Since cholesterol lowering medications in most cases do not reduce Lp(a) levels to a desirable degree it is tempting to combine them with compounds of this invention. According to one embodiment the polyhydroxylated bile acid is therefore administered in combination with a cholesterol synthesis inhibitor such as a statin or a cholesterol absorption inhibitor, e.g., Ezetimibe®.
[0056] The term “plasma level of lipoprotein (a)" according to the present invention refers to the concentration of Lp(a) in plasma given in mg/dL or nmol/L. [0057] According to one embodiment, a subject with an increased plasma level of Lp(a) compared to a desirable reference value plasma level of Lp(a) is treated with a polyhydroxylated bile acid. Thereby, the desirable reference value of plasma lipoprotein(a) is considered as the value of plasma Lp(a) associated with a no or low cardiovascular risk. Said desirable value may vary regionally worldwide. As an exemplary desirable reference value of plasma Lp(a), a concentration of below 15 mg/dl or even of below 10 mg/dl is generally considered as a plasma level of Lp(a) associated with no or low cardiovascular risk. Whereas a plasma level of Lp(a) of above 30 mg/dl is considered as increased level associated with an increased risk. A plasma level of Lp(a) of above 60 mg/dl is considered as a condition where a therapeutic intervention is generally recommended by health professionals especially if co-occurring with additional risk factors such as high plasma LDL or low plasma HDL levels.
[0058] In another embodiment, upon treatment of a subject with the polyhydroxylated bile acid compound for use according to the present invention, the plasma level of Lp(a) of said subject is decreased by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, or at least 60% as compared to the baseline plasma level of Lp(a).
[0059] The term “baseline" as used herein refers to the subject's lipoprotein (a) level determined prior to or at start of treatment. This baseline is the refence value for determining the effective decrease of the Lp(a) concentration in the subject’s plasma. The Lp(a) level may be determined by enzyme immunoassays (EIAs), by an immunoradiometric assay (IRMA), turbidimetry, nephelometry, liquid chromatography- mass spectroscopy, or by electrophoresis measuring Lp(a)- cholesterol.
[0060] In another aspect, the present invention provides a pharmaceutical composition for use in the prevention or treatment of a disease associated with an increased plasma level of Lp(a), wherein said pharmaceutical composition comprises a polyhydroxylated bile acid compound and a pharmaceutical acceptable carrier.
[0061] The term “pharmaceutically acceptable carrier" refers to a pharmaceutical carrier according to acceptable pharmaceutical techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration. Various organic or inorganic carrier materials conventionally used as materials for pharmaceutical preparations may be used as pharmaceutically acceptable carrier for the compounds of the invention and the route of administration chosen. They are blended as excipient, lubricant, binder or disintegrant for solid preparations; and solvent, solubilizing agent, suspending agent, isotonicity agent, buffer, soothing agent and the like for liquid preparations. Where necessary, an additive for pharmaceutical preparations such as preservative, antioxidant, colorant, sweetening agent and the like can be used. [0062] The term "treatment" in relation to a given disease or disorder, includes, but is not limited to, inhibiting the disease or disorder, for example, arresting the development of the disease or disorder; relieving the disease or disorder, for example, causing regression of the disease or disorder; or relieving a condition caused by or resulting from the disease or disorder, for example, relieving, preventing or treating symptoms of the disease or disorder. The term "prevention"
in relation to a given disease or disorder means: preventing the onset of disease development if none had occurred, preventing the disease or disorder from occurring in a subject that may be predisposed to the disorder or disease but has not yet been diagnosed as having the disorder or disease, and/or preventing further disease/disorder development if already present.
[0063] In one aspect, the present invention relates to the treatment and prevention of a disease associated with an increased plasma level of Lp(a), wherein said associated disease refers to a disease, disorder of condition of a subject having family and/or personal histories of heart disease, lipid metabolism disorder, hypercholesterolemia, hypertriglyceridemia, dyslipidemia, high triglycerides and/or high blood cholesterol levels, non-fatal heart attack, non-fatal stroke, postmenopausal subjects with increased risk factors for heart disease, hypothyroidism, underactive thyroid gland, diabetes, renal disease, renal failure, nephrotic syndrome, hypertension, hemostasis disorders, thrombosis, aortic valve calcification.
[0064] In a further aspect, the disease associated with an increased plasma level of Lp(a) is selected from the group consisting of atherosclerosis; stroke; vascular disease, e.g., cardiovascular disease, peripheral vascular disease, hereditary vascular disease; thrombosis; diabetes; metabolic disease conditions, e.g., dyslipoproteinemia, hyperlipidemia, etc.
[0065] In a specific aspect, the disease associated with an increased plasma level of Lp(a) is type II diabetes, hyperlipidemia, or dyslipidemia.
Examples
[0066] The Examples which follow are set forth to aid in the understanding of the invention but are not intended to, and should not be construed to limit the scope of the invention in any way. The Examples do not include detailed descriptions of conventional methods. Such methods are well known to those of ordinary skill in the art.
Example 1 -3a,6a,7a,12a-tetrahydroxy-5/3-cholan-24-oic acid reduces Apo(a) expression in transgenic Apo(a) mice - in vitro
Material and Methods of in vitro experiments:
[0067] For the experiments, transgenic (tg) mice generated according to Frazer KA. et al. 1995 (Frazer KA, et al. (1995) Nat Genet. 1995;9(4):424-431) were used. The mice carrying a 110-kb human APOA gene surrounded by more than 60- kb
5' -and 3' -flanking DNA in the YAC were the same as reported in previously (Chennamsetty, I. et al. (2011) J. din. Invest. 121: 3724 - 3734; Chennamsetty, I., et al. (2012) Arterioscier. Thromb. Vase. Biol. 32: 1220 - 1227; and Chennamsetty, I. et al. (2012) J. Lipid Res. 53: 2405-2412). 3a,6a,7a,12a-tetrahydroxy-5 b -cholan-24- oic acid (MF: C24H40O6 MW: 424.57) > 95% purity was purchased from UHN Shanghai 88 Cailun Rd, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, 201210, China. All other chemicals were from Sigma-Aldrich https://www.sigmaaldrich.com if not stated otherwise.
[0068] in vitro experiments were carried out with primary hepatocytes prepared as described previously (Salonpaa P., et al. (1994) Biochem BiophysRes CC>/77/77Z//7.205:631-637) and outlined previously (Chennamsetty, I., et al (2012) J. Lipid Res. 53: 2405-2412). In short, two 3 months old tg Apo(a) mice kept on a Altromin 1324 chow diet were sacrificed the livers were harvested and perfused with collagenase solution. After filtration and centrifugation, cells from 2 livers were mixed and re-suspended in DMEM supplemented with 20% (v/v) FCS and 100 units/ml of penicillin and streptomycin respectively. Cells were placed in 6-well collagen coated plates and cultivated in DMEM/10% FCS for 24 h before treatment with 3a,6a,7a,12a-tetrahydroxy-5 3 -cholan-24-oic acid.
Results of in vitro experiments:
[0069] Liver explants from 2 transgenic Apo(a) mice (tg-mice) on standard rodent diet 1324 from Altromin (Germany) were harvested and primary hepatocytes were prepared as described in Methods. The cells were then incubated for 24 h with 0.1 mM and 0.2 mM of 3a,6a,7a,12a-tetrahydroxy-5 b -cholan-24-oic acid and Apo(a) mRNA expression was measured by real-time PCR (RT-PCR). The results shown in Fig.l represent the mean ± SEM of three independent experiments. For comparison we also measured in the primary hepatocytes from tg-mice the expression Cyp7al the key enzyme of bile acid biosynthesis. The results are shown in Fig. 2.
Example 2 - 3a,6a,7a,12a-tetrahydroxy-5¾-cholanoic acid reduces Apo(a) expression in transgenic Apo(a) mice - in vivo
Material and Methods of in vivo and ex vivo experiments:
For the experiments, transgenic (tg) mice generated previously (Frazer KA et al. (1995) Nat Genet. 1995;9(4):424-431) were used. The mice carrying a 110-kb human APOA gene surrounded by more than 60- kb 5' -and 3' -flanking DNA in
the YAC were the same as reported in detail previously (Chennamsetty, I., et al. (2011) J. Clin. Invest. 121: 3724 - 3734; Chennamsetty, I., et al (2012) Arterioscler. Thromb. Vase. Biol. 32: 1220 - 1227; Chennamsetty, I., et al (2012) J. Lipid Res. 53: 2405-2412). As representative THBA, 3a,6a,7a,12a-tetrahydroxy-5 b -cholan-24- oic acid (MF: C24H40O6 MW: 424.57) > 95% purity was purchased from UHN Shanghai 88 Cailun Rd, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, 201210, China. All other chemicals were from Sigma-Aldrich https://www.sigmaaldrich.com if not stated otherwise.
[0070] In vivo experiments were carried out with 2- 3 months old ig-A OA mice kept on chow diet. On day zero, the animals received for 2 weeks chow diet supplemented 0.1%, 0.2%, and 1% of 3a,6a,7a,12a-tetrahydroxy-5 3 -cholan-24-oic acid. After one and 2 weeks feeding, blood was harvested from the animals for analysis of different serum parameters.
[0071] mRNA expression was measured in primary hepatocytes as well as in whole liver extracts as described previously (Chennamsetty, I., et al. (2011) J. Clin. Invest. 121: 3724 - 3734; Chennamsetty, I., et al. (2012) Arterioscler. Thromb. Vase. Biol. 32: 1220 - 1227; Chennamsetty, I., et al. (2012) J. Lipid Res. 53: 2405-2412). In short, total RNA was extracted using Trizol (Invitrogen) according to the manufacturer’s protocol. Two micrograms of total RNA were reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative real-time PCR was performed on a Light Cycler 480 instrument (Roche Diagnostics), using the QuantiFast SYBR Green PCR Kit (Qiagen). The following primer were used: Apo(a) mouse: Forward primer (5’ 3’) GGCACGTATGGCAGCAAGAT (SEQ ID NO:l); Reverse primer (5’ 3’) CCAAGGAGGAGGATTCAAACTG (SEQ ID NO:2); Ppia mouse: Forward primer (5’ 3’) TTCCAGGATTCATGTGCCAG (SEQ ID NO:3); Reverse primer (5’ 3’) CCATCCAGCCATTCAGTCTT (SEQ ID NO:4). Cyp7Al mouse: Forward primer (5’ 3’) GGGATTGCTGTGGTAGTGAGC (SEQ ID NO:5); Reverse primer (5’ 3’) GGTATGGAATCAACCCGTTGTC (SEQ ID NO:6).
[0072] The gene expression values were normalized to cyclophilin A {Ppia) as a housekeeping gene. The data were analyzed by the public domain program Relative Expression Software Tool (REST; http://www.gene- quantification. de/download. html#rest ). Values are presented as mean ± SEM.
[0073] Blood parameters: Lp(a) concentrations were measured in plasma of tg- mice using the ELISA from Mercodia® (https://www.mercodia.com/product/lp-a- ELISA) in duplicates according to the protocol of the manufacturer. Glucose was measured in whole blood by an Accu-Check Active with the commercial strips from the manufacturer. All other parameters were assayed in plasma using the Cobas (ROCHE) auto-analyzer with the reagents and protocols from the manufacturer. Example 3 - 3a,6a,7a,12a-tetrahydroxy-5/3-cholan-24-oic acid reduces Apo(a) plasma concentrations in transgenic Apo(a) mice - in vivo Results of in vivo experiments:
[0074] Feeding with 0.1% 3a,6a,7a,12a-tetrahydroxy-5 3 -cholan-24-oic acid for 1 week: 8 tg-Apo(a) mice were fed for 1 week with chow containing 0.1% (w/w)
3a, 6a, 7a, 12a-tetra hydroxy-5 b -cholan-24-oic acid. At the end of this feeding period, the animals were sacrificed, livers were harvested and the expression of Apo(a) mRNA and in comparison of Cyp7al was measured by RT-PCR as described (Fig.3). The results are mean ± SEM.
[0075] Feeding with 0.2% 3a,6a,7a,12a-tetrahydroxy-5 3 -cholan-24-oic acid for 2 weeks: 6 tg-Apo(a) mice were fed for one week with 0.2% (w/w) 3a, 6a, 7a, 12a- tetrahydroxy-5 b -cholan-24-oic acid mixed to standard rodent chow. At the end of this feeding period, blood was harvested and plasma Apo(a) concentrations were measured as described in Methods. The results are shown in Fig.4. At the x-axis the individual mice are numbered from 1-6; y-axis : Apo(a) concentrations in mg/dl. [0076] Feeding with 1% 3a,6a,7a,12a-tetrahydroxy-5 3 -cholan-24-oic acid for 1 and 2 weeks: In subsequent experiments 6 tg Apo(a) mice were fed for 2 weeks with 1% (w/w) 3a,6a,7a,12a-tetrahydroxy-5 b -cholan-24-oic acid mixed to standard rodent chow and plasma Apo(a) values were analyzed 1 week and 2 weeks after the start. The results are shown in Fig. 5. At the x-axis the individual mice are numbered from 1-6; y-axis : Apo(a) concentrations in mg/dl.
[0077] Evaluation of potential toxic effects: In order to evaluate any adverse or toxic effect of the 3a,6a,7a,12a-tetrahydroxy-5 b -cholan-24-oic acid, the body weight and the laboratory parameters glucose, urea, bilirubin, AST, ALT, and CHE were analyzed at one-week and two-week time points after starting the experiment with 1% (w/w) 3a,6a,7a,12a-tetrahydroxy-5 b -cholan-24-oic acid feeding. As shown in Table 1 no signs of toxicity or intolerance could be observed.
Table 1: Laboratory parameters of 6 mice treated for 2 weeks with 3a, 6a, 7a, 12a- tetrahydroxy-5 b -cholan-24-oic acid
[0078] Interpretation and discussion: As previously shown (Chennamsetty et al, (2011) J. din. Invest. 121: 3724 - 3734) plasma Lp(a) concentrations are determined by the production rate (expression) of Apo(a) in the liver. The expression of human genes in general is strongly influenced by transcription factors and nuclear receptors. There are at least 70 response elements in the promoter region of the Apo(a) gene. Two mechanisms have been suggested to be responsible for Apo(a) expression, both sensitive to farnesoid-X receptor (FXR) agonists. A known FXR agonist is cholic acid (3 a ,7 a ,12 a -trihydroxy-5 b -cholan- 24-oic acid), that in fact reduced plasma Apo(a) concentrations when fed to tg- Apo(a) mice. Due to its unwanted side effects cholic acid is not recommended for use as a medication because it may cause liver damage.
[0079] Surprisingly, it was demonstrated here, that the non-toxic polyhydroxylated bile acid 3a,6a,7a,12a-tetrahydroxy-5 3 -cholan-24-oic acid is effective in reducing plasma Apo(a) in tg-Apo(a) mice. 3a,6a,7a,12a-tetrahydroxy-5 3 -cholan-24-oic acid interferes in Apo(a) transcription by reducing mRNA abundance in liver of tg- Apo(a) mice. From this surprising result it can be concluded that polyhydroxylated bile acids are effective in decreasing the Lp(a) level in subject’s plasma and thus, prevent or treat diseases which are associated with an increased Lp(a) level.
Claims
1. A polyhydroxylated bile acid compound or a pharmaceutically acceptable salt thereof for use in the treatment of a subject suffering from an increased plasma level of lipoprotein (a) (Lp(a)).
2. The compound for use of claim 1, wherein the plasma level of Lp(a) in said subject is above 30 mg/dl.
3. The compound for use of claim 1 or 2, wherein the plasma level of Lp(a) in said subject is decreased by at least 10% compared to a baseline value.
4. The compound for use of any one of the preceding claims, wherein the polyhydroxylated bile acid compound is conjugated to a pharmaceutically acceptable moiety.
5. The compound for use of claim 4, wherein the pharmaceutically acceptable moiety is selected from the group consisting of amino sulfonic acid, an amine and amino acid.
6. The compound for use of claim 5, wherein the pharmaceutically acceptable moiety is selected from the group consisting of ethanolamine, taurine, glycine or serine.
7. The compound for use of any one of preceding claims, wherein the polyhydroxylated bile acid compound is a tetrahydroxylated bile acid.
8. The compound for use of claim 7, wherein the tetrahydroxylated bile acid is selected from the group consisting of
3.6.7.12-tetrahydroxy-cho la n-24-oic acid,
3.4.7.12-tetrahydroxy-cho la n-24-oic acid,
1.3.7.12-tetrahydroxy-cho la n-24-oic acid,
2.3.7.12-tetrahydroxy-cho la n-24-oic acid,
2.4.7.12-tetrahydroxy-cholan-24-oic acid, and
2.6.7.12-tetrahydroxy-cho la n-24-oic acid.
9. The compound for use of claim 7, wherein the tetrahydroxylated bile acid is selected from the group consisting of
3a,6a,7a,12a-tetrahydroxy-5 3 -cholan-24-oic acid,
3a, 6/3 ,7a,12a-tetrahydroxy-5 b -cholan-24-oic acid,
3a, 6a, 7 b ,12a-tetra hydroxy-5 b -cholan-24-oic acid,
3a, 6a, 7a, 12/3 -tetrahydroxy-5 b -cholan-24-oic acid,
3a, 6/3 ,7a, 12/3 -tetrahydroxy-5 b -cholan-24-oic acid,
3a, 6/3 ,7 b ,12/3 -tetra hyd roxy-5 b -cholan-24-oic acid, and 1 b ,3a, 7a, 12a- tetrahydroxy-cholan-24-oic acid.
10. The compound for use of claim 1, wherein the polyhydroxylated bile acid is 3a,6a,7a,12a-tetrahydroxy-5/3 -cholan-24-oic acid.
11. The compound for use of any of the preceding claims, wherein the increased plasma level of Lp(a) of the subject is the cause of an associated disease.
12. The compound for use of claim 11, wherein the associated disease is one of hyperlipidemia, dyslipidemia, atherosclerosis, hypertension, thrombosis, disorder of hemostasis, cardiovascular disease, aortic calcification, stroke, kidney disease or Type-ll diabetes.
13. The compound for use of any of claims 1 - 12, wherein the polyhydroxylated bile acid is used in combination with a cholesterol lowering agent.
14. The compound for use of claim 13, wherein the cholesterol lowering agent is a cholesterol synthesis inhibitor or a cholesterol absorption inhibitor.
15. A pharmaceutical composition for use in the prevention or treatment of a disease associated with an increased Lp(a) plasma level in a subject comprising a polyhydroxylated bile acid compound according to any of claims 1 to 12 and a pharmaceutical acceptable carrier.
16. The pharmaceutical composition for use of claim 15, wherein the disease is one of hyperlipidemia, dyslipidemia, atherosclerosis, hypertension, thrombosis, disorder of hemostasis, cardiovascular disease, aortic calcification, stroke, kidney disease or Type-ll diabetes.
17. The pharmaceutical composition for use of claim 16, wherein the disease is hyperlipidemia, dyslipidemia, hypertension, or Type-ll diabetes.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2021/061679 WO2022233398A1 (en) | 2021-05-04 | 2021-05-04 | COMPOUNDS FOR REDUCING LIPOPROTEIN(a) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2021/061679 WO2022233398A1 (en) | 2021-05-04 | 2021-05-04 | COMPOUNDS FOR REDUCING LIPOPROTEIN(a) |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022233398A1 true WO2022233398A1 (en) | 2022-11-10 |
Family
ID=75801599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2021/061679 WO2022233398A1 (en) | 2021-05-04 | 2021-05-04 | COMPOUNDS FOR REDUCING LIPOPROTEIN(a) |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022233398A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009105897A1 (en) | 2008-02-26 | 2009-09-03 | British Columbia Cancer Agency Branch | Polyhydroxylated bile acids for treatment of biliary disorders |
WO2011022838A1 (en) | 2009-08-25 | 2011-03-03 | British Columbia Cancer Agency Branch | Polyhydroxylated bile acids for treatment of biliary disorders |
WO2013041519A1 (en) | 2011-09-19 | 2013-03-28 | ETH Zürich, ETH Transfer | Ror gamma modulators |
WO2014184271A1 (en) * | 2013-05-14 | 2014-11-20 | Tes Pharma Srl. | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators |
-
2021
- 2021-05-04 WO PCT/EP2021/061679 patent/WO2022233398A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009105897A1 (en) | 2008-02-26 | 2009-09-03 | British Columbia Cancer Agency Branch | Polyhydroxylated bile acids for treatment of biliary disorders |
WO2011022838A1 (en) | 2009-08-25 | 2011-03-03 | British Columbia Cancer Agency Branch | Polyhydroxylated bile acids for treatment of biliary disorders |
WO2013041519A1 (en) | 2011-09-19 | 2013-03-28 | ETH Zürich, ETH Transfer | Ror gamma modulators |
WO2014184271A1 (en) * | 2013-05-14 | 2014-11-20 | Tes Pharma Srl. | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators |
Non-Patent Citations (9)
Title |
---|
CHENNAMSETTY INDUMATHI ET AL: "Farnesoid X receptor represses hepatic human APOA gene expression", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 121, no. 9, 1 September 2011 (2011-09-01), GB, pages 3724 - 3734, XP055877143, ISSN: 0021-9738, DOI: 10.1172/JCI45277 * |
CHENNAMSETTY, I. ET AL., ARTERIOSC/ER. THROMB. VASE. BIOL., vol. 32, 2012, pages 1220 - 1227 |
CHENNAMSETTY, I. ET AL., ARTERIOSCLER. THROMB. VASE. BIOL., vol. 32, 2012, pages 1220 - 1227 |
CHENNAMSETTY, I. ET AL., J. CLIN. INVEST., vol. 121, 2011, pages 3724 - 3734 |
CHENNAMSETTY, I. ET AL., J. LIPID RES., vol. 53, 2012, pages 2405 - 2412 |
FRAZER KA ET AL., NAT GENET, vol. 9, no. 4, 1995, pages 424 - 431 |
KOSTNER K. M. ET AL: "When should we measure lipoprotein (a)?", EUROPEAN HEART JOURNAL, vol. 34, no. 42, 2 November 2013 (2013-11-02), GB, pages 3268 - 3276, XP055877130, ISSN: 0195-668X, Retrieved from the Internet <URL:https://watermark.silverchair.com/eht053.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAugwggLkBgkqhkiG9w0BBwagggLVMIIC0QIBADCCAsoGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMxxN9Pe178lL8p91aAgEQgIICm6_Nqpt6CklWw5PhlXpdcB6HW9nWbFBnggccIy7IB4z8_tgqzKIsHyMkRz-Xjv6CEb9JJzIHIfoRkNfOdXXBt5AUGTnPR> DOI: 10.1093/eurheartj/eht053 * |
KOSTNER, K.M. ET AL., EUROPEAN HEART JOURNAL, vol. 34, 2013, pages 3268 - 3276 |
SALONPAA P. ET AL., BIOCHEM BIOPHYSRES COMMUN, vol. 205, 1994, pages 631 - 637 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Charlton‐Menys et al. | Human cholesterol metabolism and therapeutic molecules | |
Sorokin et al. | Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review | |
Chapman et al. | Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors | |
JP2021155436A (en) | Method of using cyclodextrin | |
Reitsma et al. | Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor | |
Elbers et al. | Thyroid hormone mimetics: the past, current status and future challenges | |
Gordon et al. | The effect of cortisone on the serum lipids and on the development of experimental cholesterol atherosclerosis in the rabbit | |
Luo et al. | Resistin-induced endoplasmic reticulum stress contributes to the impairment of insulin signaling in endothelium | |
US20050032761A1 (en) | Lipid profile modulation | |
Raparti et al. | Selective thyroid hormone receptor modulators | |
Bays et al. | Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus | |
Iglesias et al. | New drugs for the treatment of hypercholesterolaemia | |
Derfler et al. | Decreased postheparin lipolytic activity in renal transplant recipients with cyclosporin A | |
US20220265614A1 (en) | Treatment comprising fxr agonists | |
WO2022233398A1 (en) | COMPOUNDS FOR REDUCING LIPOPROTEIN(a) | |
Brunton et al. | Lipopheresis in the nephrotic syndrome | |
IL268708A (en) | Pharmaceutical compositions for combination therapy | |
US20220265619A1 (en) | Combination treatment of liver diseases using fxr agonists | |
Marino et al. | Hormone action and liver disease, a complex interplay | |
RU2093153C1 (en) | 5-[2-(tert-butylamino)-1-hydroxyethyl]-meta-phenylene-bis-(di- -methylcarbamate) (bambuterin) as hypolipidemic preparation and pharmaceutical composition based on bambuterin | |
Zhou et al. | Artemisinin inhibits glycosaminoglycan chain synthesizing gene expression but not proliferation of human vascular smooth muscle cells | |
US20210290580A1 (en) | New use of carbamate ß phenylethanolamine analogues for enhancing intracellular clearance of LDL cholesterol and for combining therapy with statins to enhance the efficacy and reduce adverse effects | |
Kasim et al. | Amiodarone-induced changes in lipid metabolism | |
Haredy et al. | Effect of sildenafil citrate on prediabetic and diabetic albino rats treated with metformin | |
US20230052189A1 (en) | Treatment of primary biliary cholangitis with elafibranor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21723711 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |